Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4190MR)

This product GTTS-WQ4190MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4190MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6759MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ1899MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ8665MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ6158MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ11856MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ10760MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ10776MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ6289MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW